"Panel to Study Expediting Drug Development Process"

var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www."); document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E")); ion" CONTENT="The goal of a new national committee established by the President s Cancer Panel is to undertake a systematic study of drug regulation as it affects available AIDS and cancer therapies and to suggest improvements in the system, according to Dr. Thomas Merigan of Stanford University s School of Medicine. Merigan, one"> "Panel to Study Expediting Drug Development Process" < > // var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www."); document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E")); > < > // var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www."); document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E")); >

Important note: Information in this article was accurate in 1988. The state of the art may have changed since the publication date.

"Panel to Study Expediting Drug Development Process"

Bay Area Reporter (12/29/88) Vol. 18, No. 52, P. 13

Abstract: The goal of a new national committee established by the President's Cancer Panel is to undertake a systematic study of drug regulation as it affects available AIDS and cancer therapies and to suggest improvements in the system, according to Dr. Thomas Merigan of Stanford University's School of Medicine. Merigan, one of nine members of the National Committee to Review Current Procedures for Approval of New Drugs, says the efficiency of drug testing must be improved without compromising the rigor and quality of the drug evaluation process. Dr. Louis Lasagna of Tufts University is chairman of the commission, which will include representatives from the academic and industry communities. Merigan says that in the face of the recent Food and Drug Administration to fast-track some AIDS therapies, "the question is, do we want to change the system even more radically?" George Bush, whose Presidential Task Force on Regulatory Relief initiated the idea of the commission, also wants it to examine the appropriate endpoints for determining the effectiveness of new treatments, and the latitude researchers should have in modifying approved investigational protocols.
881229
AD880006

Copyright © 1988 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

< type="text/java "> var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www."); document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E")); > < type="text/java " src="http://pagead2.googlesyndication.com/pagead/show_ads.js"> var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www."); document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E")); >

AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 1988. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1988. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .